Dr Urbanucci is group leader within the prostate cancer research centre (PCRC) at the Faculty of Medicine and Health Technology (MET) within the Tampere University, and currently researching prostate cancer at a single cell analysis resolution with emphasis on tumor microenvironment and radiobiology. He is also Senior Research Fellow at the Tampere Institute for advanced Studies, project group leader at the Institute for Cancer Research (ICR- Oslo University Hospital), and associate investigator of the Norwegian Centre for Molecular Medicine (NCMM) - EMBL partnership (University of Oslo).
Dr Urbanucci graduated from the University of Perugia, in Italy, and obtained a PhD in cancer genetics and molecular biology of cancer in Finland, at the University of Tampere, in 2012. He researched transcriptional and chromatin drivers underpinning prostate cancer progression with the androgen receptor as a focal point. He initially published a series of papers regarding the molecular effects of the deregulation of the androgen receptor on the chromatin and transcription, and how these effects drive prostate cancer progression. He then investigated the mechanisms of action of bromodomain inhibitors and derived novel prognostic tools for patients stratification into novel therapeutics.